Corvus Pharmaceuticals Inc - Asset Resilience Ratio
Corvus Pharmaceuticals Inc (CRVS) has an Asset Resilience Ratio of 82.05% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Corvus Pharmaceuticals Inc (CRVS) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2025)
This chart shows how Corvus Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Corvus Pharmaceuticals Inc (CRVS) total assets.
Liquid Assets Composition Over Time
This chart breaks down Corvus Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore long-term investment intensity of Corvus Pharmaceuticals Inc to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $196.32 Million | 82.05% |
| Total Liquid Assets | $196.32 Million | 82.05% |
Asset Resilience Insights
- Very High Liquidity: Corvus Pharmaceuticals Inc maintains exceptional liquid asset reserves at 82.05% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Corvus Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Corvus Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Corvus Pharmaceuticals Inc (2015–2025)
The table below shows the annual Asset Resilience Ratio data for Corvus Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 73.36% | $52.17 Million | $71.12 Million | +10.63pp |
| 2024-12-31 | 62.73% | $43.22 Million | $68.91 Million | +30.83pp |
| 2023-12-31 | 31.89% | $14.53 Million | $45.55 Million | -10.81pp |
| 2022-12-31 | 42.71% | $29.14 Million | $68.24 Million | +37.23pp |
| 2021-12-31 | 5.48% | $5.99 Million | $109.45 Million | -27.03pp |
| 2020-12-31 | 32.51% | $27.80 Million | $85.53 Million | -54.56pp |
| 2019-12-31 | 87.07% | $72.83 Million | $83.65 Million | +23.29pp |
| 2018-12-31 | 63.77% | $75.40 Million | $118.23 Million | +16.35pp |
| 2017-12-31 | 47.43% | $44.95 Million | $94.78 Million | -45.22pp |
| 2016-12-31 | 92.65% | $129.85 Million | $140.15 Million | +0.95pp |
| 2015-12-31 | 91.69% | $90.28 Million | $98.46 Million | -- |
About Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-cen… Read more